Little Known Facts About ABBV-744 as a potential therapeutic option for aggressive cancers.
The present work examined the potential of employing ARV-825 and ABBV-744 to increase the effectiveness of tamoxifen or fulvestrant as well as palbociclib. ARV-825 was effective in both p53 wild-variety (WT) breast tumor cells and in cells lacking functional p53 either on your own or in combination with tamoxifen, when the effectiveness of ABBV-744